An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...

Ketamine’s promising potential to ease depression is one of the reasons why its use has recently skyrocketed in the US and ...

Recreational ketamine use has increased in the United States in recent years, outpacing its rise as a treatment for depression, a new analysis suggests. The hallucinogenic drug — a controlled ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

A bunch of evidence has shown that ketamine could be used in therapy for depression, although how it achieves this remains somewhat unclear. In a new study, tiny zebrafish suffering from a sense ...